Linifanib ≥95%

Supplier: ADIPOGEN CORP MS

Synonyms: 1-(4-(3-Amino-1H-indazol-4-yl)phenyl)-3-(2-fluoro-5-methylphenyl)urea, ABT-869

SYN-1002-M001 SYN-1002-M005 SYN-1002-M010 SYN-1002-M050
102991-180EA 119.08 USD
102991-180 102991-182 102991-184 102991-186
Linifanib ≥95%
Linifanib

Linifanib (A 741439; A-741439; A741439; ABT-869; ABT869; RG3635) is an orally active multi-targeted receptor tyrosine kinase inhibitor for the treatment of various cancers. The compound is designed to inhibit vascular endothelial growth factor and platelet-derived growth factor receptors and is a multitargeted tyrosine kinase receptor inhibitor that suppresses FLT3 signaling. It is in phase III development for liver cancer and phase II development for non-small cell lung cancer, breast cancer, and colorectal cancer. Recent research also indicates that Linifanib inhibits proliferation and induces apoptosis in AML patient cells via reduction of AKT and GSK3beta phosphorylation and maybe influencial in AML therapy.

Formula: C₂₁H₁₈FN₅O
MW: 375.4 g/mol
Storage Temperature: Freezer
MDL Number: MFCD11840918
CAS Number: 796967-16-3

Order Now

Specification Test Results

Purity 95%
Appearance/Color Solid.
Solubility Soluble in DMSO or ethanol.

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR